| Title: |
Endocrine therapy in advanced high-grade ovarian cancer: real-life data from a multicenter study and a review of the literature |
| Authors: |
Aubert, Marine; Mathiot, Laurent; Vegas, Hélène; Ouldamer, Lobna; Linassier, Claude; Augereau, Paule; Bocquet, François; Frenel, Jean-Sébastien; Cancel, Mathilde |
| Source: |
The Oncologist ; volume 29, issue 7, page e910-e917 ; ISSN 1083-7159 1549-490X |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2024 |
| Description: |
Background In women, ovarian cancer is the eighth most frequent cancer in incidence and mortality. It is often diagnosed at advanced stages; relapses are frequent, with a poor prognosis. When platinum resistant, subsequent lines of chemotherapy are of limited effect and often poorly tolerated, leading to quality of life deterioration. Various studies suggest a hormonal role in ovarian carcinogenesis, with a rationale for endocrine therapy in these cancers. Patients and Methods This multicenter, retrospective study assessed the use of endocrine treatment for high-grade ovarian epithelial carcinomas treated between 2010 and 2020. Results Eighty-one patients with ovarian cancers were included. The median duration of platinum sensitivity was 29 months. We observed a 35% disease control rate with endocrine therapy, and 10% reported symptom improvement. For 19 patients (23.5%), the disease was stabilized for more than 6 months. Median overall survival from diagnosis was 62.6 months. Regarding endocrine therapy predictive factors of response, in a multivariate analysis, 3 factors were statistically significant in favoring progression-free survival: platinum sensitivity (P = .021), an R0 surgical resection (P = .020), and the indication for hormone therapy being maintenance therapy (P = .002) Conclusion This study shows real-life data on endocrine therapy in ovarian cancer. As it is a low-cost treatment with many advantages such as its oral administration and its safety, it may be an option to consider. A perspective lies in the search for cofactors to aim as future therapeutic targets to improve the effectiveness of hormone treatment by means of combination therapy. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/oncolo/oyae093 |
| Availability: |
https://doi.org/10.1093/oncolo/oyae093; https://academic.oup.com/oncolo/article-pdf/29/7/e910/58449006/oyae093.pdf |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.F2ACA583 |
| Database: |
BASE |